JPWO2022072447A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022072447A5 JPWO2022072447A5 JP2023520289A JP2023520289A JPWO2022072447A5 JP WO2022072447 A5 JPWO2022072447 A5 JP WO2022072447A5 JP 2023520289 A JP2023520289 A JP 2023520289A JP 2023520289 A JP2023520289 A JP 2023520289A JP WO2022072447 A5 JPWO2022072447 A5 JP WO2022072447A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- salt
- modification
- dsrna agent
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086495P | 2020-10-01 | 2020-10-01 | |
| US63/086,495 | 2020-10-01 | ||
| PCT/US2021/052580 WO2022072447A1 (en) | 2020-10-01 | 2021-09-29 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544385A JP2023544385A (ja) | 2023-10-23 |
| JP2023544385A5 JP2023544385A5 (https=) | 2024-10-07 |
| JPWO2022072447A5 true JPWO2022072447A5 (https=) | 2024-10-07 |
Family
ID=80950831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520289A Pending JP2023544385A (ja) | 2020-10-01 | 2021-09-29 | Ｓｎｃａ関連神経変性疾患を治療又は予防するためのｓｎｃａ ｉｒｎａ組成物及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240011032A1 (https=) |
| EP (1) | EP4221838A4 (https=) |
| JP (1) | JP2023544385A (https=) |
| KR (1) | KR20230079405A (https=) |
| CN (1) | CN116710107A (https=) |
| AR (1) | AR123679A1 (https=) |
| AU (1) | AU2021353935A1 (https=) |
| CA (1) | CA3193830A1 (https=) |
| IL (1) | IL301712A (https=) |
| MX (1) | MX2023003810A (https=) |
| TW (1) | TW202229551A (https=) |
| WO (1) | WO2022072447A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119630791A (zh) * | 2022-05-13 | 2025-03-14 | 迪克纳制药公司 | 用于抑制snca表达的组合物和方法 |
| US20260103703A1 (en) * | 2022-09-29 | 2026-04-16 | Atalanta Therapeutics, Inc. | siRNA COMPOSITIONS AND METHODS TARGETING ALPHA-SYNUCLEIN NUCLEIC ACIDS |
| WO2024166019A1 (en) * | 2023-02-08 | 2024-08-15 | Biorchestra Co., Ltd. | Sirna targeting alpha-synuclein and uses thereof |
| AU2024335806A1 (en) * | 2023-09-07 | 2026-04-23 | Janssen Pharmaceutica Nv | SNCA siRNA AND USES THEREOF |
| WO2025162214A1 (en) * | 2024-01-30 | 2025-08-07 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of synuclein alpha (snca) gene |
| TW202547527A (zh) * | 2024-02-08 | 2025-12-16 | 日商泰爾茂股份有限公司 | 寡核苷酸 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP2508608A1 (en) * | 2003-06-09 | 2012-10-10 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
| WO2005045034A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED TREATMENT OF PARKINSON DISEASE USING SHORT INTERERING NUCLEIC ACID (siNA) |
| US20080003570A1 (en) * | 2004-12-22 | 2008-01-03 | The General Hospital Corporation | Translation enhancer elements of genes encoding human Tau protein and human alpha-synuclein protein |
| US20100105134A1 (en) * | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
| WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
| WO2012027713A2 (en) * | 2010-08-26 | 2012-03-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of snca |
| CA3077910A1 (en) * | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| CN108728533B (zh) * | 2017-04-20 | 2022-06-14 | 常青 | 用于髓母细胞瘤分子分型的基因群以及snca基因作为4型髓母细胞瘤的生物标志物的用途 |
| AU2019207859A1 (en) * | 2018-01-12 | 2020-07-02 | Roche Innovation Center Copenhagen A/S | Alpha-synuclein antisense oligonucleotides and uses thereof |
| WO2019217459A1 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| EP3830265A1 (en) * | 2018-08-03 | 2021-06-09 | Genzyme Corporation | Variant rnai against alpha-synuclein |
-
2021
- 2021-09-29 AU AU2021353935A patent/AU2021353935A1/en active Pending
- 2021-09-29 EP EP21876366.2A patent/EP4221838A4/en active Pending
- 2021-09-29 JP JP2023520289A patent/JP2023544385A/ja active Pending
- 2021-09-29 US US18/247,314 patent/US20240011032A1/en active Pending
- 2021-09-29 CN CN202180081220.XA patent/CN116710107A/zh active Pending
- 2021-09-29 KR KR1020237014415A patent/KR20230079405A/ko active Pending
- 2021-09-29 WO PCT/US2021/052580 patent/WO2022072447A1/en not_active Ceased
- 2021-09-29 IL IL301712A patent/IL301712A/en unknown
- 2021-09-29 CA CA3193830A patent/CA3193830A1/en active Pending
- 2021-09-29 MX MX2023003810A patent/MX2023003810A/es unknown
- 2021-09-30 TW TW110136531A patent/TW202229551A/zh unknown
- 2021-10-01 AR ARP210102736A patent/AR123679A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2900821B1 (en) | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy | |
| JP2023103244A5 (https=) | ||
| US9481887B2 (en) | DNA aptamers for promoting remyelination | |
| JPWO2018056442A1 (ja) | 血液脳関門通過型ヘテロ２本鎖核酸 | |
| CA2357950C (en) | Therapeutic phosphodiesterase inhibitors | |
| JP2024511954A (ja) | ペプチド－オリゴヌクレオチド複合体を用いる筋強直性ジストロフィー１型の治療法 | |
| JPWO2022072447A5 (https=) | ||
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JPWO2021257782A5 (https=) | ||
| CA2902623A1 (en) | Locked nucleic acid inhibitor of mir-145 and uses thereof | |
| JPWO2022246251A5 (https=) | ||
| WO2026026776A1 (zh) | 抑制APP基因表达的siRNA及其缀合物和应用 | |
| TW202233839A (zh) | 用於抑制ａｌｄｈ２表現之化學修飾 | |
| JPWO2021119226A5 (https=) | ||
| RU2839721C2 (ru) | Антисмысловые олигонуклеотиды, нацеленные на ген cav3.1, и их применения | |
| EP4389892A1 (en) | Antisense oligonucleotide targeting cav3.1 gene and uses thereof | |
| JP2023525770A (ja) | 神経学的疾患を処置するための補体ｃ４阻害剤および関連する組成物、ならびにそれを使用するシステムおよび方法 | |
| RU2024129253A (ru) | КОМПОЗИЦИИ SNCA-НАПРАВЛЕННЫХ миРНК ДЛЯ ЛЕЧЕНИЯ SNCA-АССОЦИИРОВАННОГО ЗАБОЛЕВАНИЯ | |
| WO1998049287A2 (en) | Antisense oligonucleotides specific for thymidylate synthase | |
| HK40109711A (zh) | 靶向cav3.1基因的反义寡核苷酸及其用途 | |
| JPWO2023192977A5 (https=) | ||
| JPWO2022212231A5 (https=) | ||
| EP1007098B1 (en) | Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides | |
| WO2024257848A1 (ja) | 遅発性中枢毒性が低減されているアンチセンスオリゴヌクレオチドの設計方法、及びその製造方法 | |
| JP2023137052A (ja) | コンドロイチン硫酸生合成を阻害するアンチセンス核酸 |